Based on the Adaptimmune Therapeutics plc stock forecast from 0 analysts, the average analyst target price for Adaptimmune Therapeutics plc is not available over the next 12 months. Adaptimmune Therapeutics plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Adaptimmune Therapeutics plc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Adaptimmune Therapeutics plc’s stock price was EUR 0.65. Adaptimmune Therapeutics plc’s stock price has changed by +13.04% over the past week, +2.36% over the past month and +54.76% over the last year.
No recent analyst target price found for Adaptimmune Therapeutics plc
No recent average analyst rating found for Adaptimmune Therapeutics plc
Company Overview Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Read Less
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPAS...Read More
Frequently Asked Questions About Adaptimmune Therapeutics plc (473A:F) Stock
Stock Target Advisor's fundamental analysis for Adaptimmune Therapeutics plc's stock is Very Bearish.
Unfortunately we do not have enough data on 473A:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 473A:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 473A:F's stock to indicate if its overvalued.
The last closing price of 473A:F's stock was EUR 0.65.
The most recent market capitalization for 473A:F is EUR 0.14B.
Unfortunately we do not have enough analyst data on 473A:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Adaptimmune Therapeutics plc's stock.
As per our most recent records Adaptimmune Therapeutics plc has 449 Employees.
Adaptimmune Therapeutics plc's registered address is 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX.
You can get more information about it from Adaptimmune Therapeutics plc's website at https://www.adaptimmune.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Adaptimmune Therapeutics plc (473A:F) Stock
Stock Target Advisor's fundamental analysis for Adaptimmune Therapeutics plc's stock is Very Bearish.
Unfortunately we do not have enough data on 473A:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 473A:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 473A:F's stock to indicate if its overvalued.
The last closing price of 473A:F's stock was EUR 0.65.
The most recent market capitalization for 473A:F is EUR 0.14B.
Unfortunately we do not have enough analyst data on 473A:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Adaptimmune Therapeutics plc's stock.
As per our most recent records Adaptimmune Therapeutics plc has 449 Employees.
Adaptimmune Therapeutics plc's registered address is 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX.
You can get more information about it from Adaptimmune Therapeutics plc's website at https://www.adaptimmune.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 473A:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
